Supervivencia de pacientes con cáncer de pulmón de célula no peque？a en cuatro instituciones de Colombia

objective: describing results of treatment in patients suffering advanced no small cell according to routine clinical practice. the 70 % of patients suffering debut with advanced disease are determining less than 13 % overall survival in 5 years. methods: 176 patients treated in bogotá. results: the mean age was 64 years; 64 % were male 51 % had ≤1 ecog. the 90 % had metastasis, mainly in the lung and in central nervous system. 76 % received combined therapy as the first line of intervention; 126 subjects were treated with a platinum compounds (cisplatin 38/21.6 % carboplatin 88/50 %) plus some third generation agent or etoposide. thirty-four received monotherapy and eight erlotinib; 3.7 ± 1.7 cycles per patient were supplied on average, overall response rate was 29 %, clinical benefit 39 % and the median time to progression was 3.4 months. only the third part of the population received a second line intervention; in this group overall response was 15.8 %, clinical benefit 33.8 % and free time progression was 3.1 months. when follow-up finished, 69.3 % had died, median the overall survival was 9.2 months 26 % of the subjects lived for up to one year. some variables such gender, functional state, history of smoking, administering second line agent and a diagnosis of adenocarcinoma influenced in superlife. conclusions: clinical behaviour and outcomes treatment of patients included in this study were similar to those previously reported in the medical literature.